In summary, the combination of AD vector vaccine and PD-1 inhibitor can improve the stemness of tumor neoantigen-specific CD8+ T cells, maintain and promote their ability to proliferate, expand and transport to tumor sites, and promote and induce memory T cells to produce an immune response against tumors. The gene discussed is CD8A; the disease is neoplasm.